Janssen Inc. v. Teva Canada Limited, 2020 FC 87 (Paliperidone*)
Justice Manson - 2020-01-21
Read full decision. Automatically generated summary:
In the underlying action, the Plaintiffs [collectively Janssen] seek a declaration pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations that the Defendant [Teva] will infringe any of claims 1 to 48 of the ‘335 Patent. ... The ‘335 Patent is listed on the Patent Register in respect of Janssen’s INVEGA SUSTENNA® product, a long-acting injectable drug product for the treatment of schizophrenia and schizoaffective disorder. ... With the new trial date upcoming, this Order addresses the parties’ hearsay and expert qualification objections.
Decision relates to:
- T-353-18 - JANSSEN INC. ET AL v. TEVA CANADA LIMITED